Isotretinoin Plus Clindamycin Seem Highly Effective Against Severe Erlotinib-Induced Skin Rash in Advanced Non-small Cell Lung Cancer

Shepherd, 2001, Erlotinib in previously treated non-small cell lung cancer, N Eng J Med, 353, 123, 10.1056/NEJMoa050753 Robert, 2005, Cutaneous side-effects of kinase inhibitors and blocking antibodies, Lancet Oncol, 6, 491, 10.1016/S1470-2045(05)70243-6 Li, 2009, Skin toxicities associated with epidermal growth factor receptor inhibitors, Target Oncol, 4, 107, 10.1007/s11523-009-0114-0 Tiseo, 2009, An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy, Lung Cancer, 64, 199, 10.1016/j.lungcan.2008.09.001 Thatcher, 2009, Expert consensus on the management of erlotinib-associated cutaneous toxicity in the U.K., Oncologist, 14, 840, 10.1634/theoncologist.2009-0055 Gridelli, 2008, Clinical significance and treatment of skin rash from erlotinib in non small cell lung cancer patients: results of an experts panel meeting, Crit Rev Oncol Hematol, 66, 155, 10.1016/j.critrevonc.2007.10.004 Pérez-Soler, 2005, HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum, Oncologist, 10, 345, 10.1634/theoncologist.10-5-345 Skoutelis, 1993, In vivo potentiation of polymorphonuclear leukocyte chemotaxis by clindamycin, Infection, 21, 321, 10.1007/BF01712455 Rayner, 2006, Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus, Intern Med J, 36, 142 Vezzoli, 2008, Cetuximab induced acneiform eruption and the response to isotretinoin, Acta Derm Venereol, 88, 84, 10.2340/00015555-0330 Gutzmer, 2005, Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy, Br J Dermatol, 153, 849, 10.1111/j.1365-2133.2005.06835.x Falcon, 1986, In vitro effect of isotretinoin on monocyte chemotaxis, J Invest Dermatol, 86, 550, 10.1111/1523-1747.ep12355006 Trotti, 2003, CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment, Semin Radiat Oncol, 13, 176, 10.1016/S1053-4296(03)00031-6 Perez-Soler, 2005, Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?, J Clin Oncol, 23, 5235, 10.1200/JCO.2005.00.6916 Wacker, 2007, Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies, Clin Cancer Res, 1, 3913, 10.1158/1078-0432.CCR-06-2610